Melanie Sheppard, PA
Medical · Orangeburg, SCNPI 1659658185
Payments from drug & device makers
Across 71 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$200
- Lilly USA, LLC$197
- AbbVie$182
- Abbott$114
- GSK$57
- Boehringer Ingelheim$54
- plus $375 from 15 others
What the payments were for
- Food & beverage$1,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $200 |
| Lilly USA, LLC | 11 | $197 |
| AbbVie | 15 | $182 |
| Abbott | 6 | $114 |
| GSK | 4 | $57 |
| Boehringer Ingelheim | 3 | $54 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| AstraZeneca(2 entities) | 2 | $32 |
| Novartis | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Pfizer | 2 | $26 |
| Amgen | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Cvrx, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,179 in reported general payments places this provider in the 55th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $122,039 |
| JardianceEmpagliflozin | 113 | $107,405 |
| MounjaroTirzepatide | 83 | $95,740 |
| JanuviaSitagliptin Phosphate | 102 | $83,492 |
| FarxigaDapagliflozin Propanediol | 85 | $58,696 |
| EliquisApixaban | 60 | $45,162 |
| TradjentaLinagliptin | 26 | $17,515 |
| TrulicityDulaglutide | 15 | $16,057 |
| LinzessLinaclotide | 28 | $15,954 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,933 |
| CreonLipase/Protease/Amylase | 13 | $9,062 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,530 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,481 |
| Rosuvastatin Calcium | 396 | $6,790 |
| Pravastatin Sodium | 504 | $5,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $54 | $124,920139 claims |
| Novo NordiskOzempic | $200 | $122,039111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $197 | $111,79798 claims |
| AstraZenecaFarxiga, Symbicort | $32 | $66,225107 claims |
| PfizerEliquis, Premarin | $26 | $47,94873 claims |
| AbbVieLinzess, Creon | $182 | $25,01641 claims |
| GSKBreo Ellipta, Anoro Ellipta | $57 | $11,24226 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $5,67713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 384 medical providers in South Carolina.
Other medical in Orangeburg
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.